{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:57:57Z","timestamp":1761674277443,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,5,3]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This <jats:italic>post hoc<\/jats:italic> analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125\u2009mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) \u22643.6\u2009and &lt;2.6, Health Assessment Questionnaire-Disability Index reduction from baseline \u22650.35 and radiographic non-progression (defined as change from baseline \u22640 in PsA-modified total Sharp\/van der Heijde score). Responses were stratified by baseline BMI (underweight\/normal, &lt;25\u2009kg\/m<jats:sup>2<\/jats:sup>; overweight, 25\u201330\u2009kg\/m<jats:sup>2<\/jats:sup>; obese, &gt;30 kg\/m<jats:sup>2<\/jats:sup>) and compared in univariate and multivariate models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 212\/213 and 210\/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight\/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight\/normal subgroup. In the placebo group, patients in the obese versus underweight\/normal subgroup were significantly less likely to achieve DAS28 (CRP) &lt;2.6 at week 24 (OR 0.26; 95% CI 0.08 to 0.87; p=0.03).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01860976\">NCT01860976<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000934","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T06:49:07Z","timestamp":1559285347000},"page":"e000934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc<\/i> analysis of a phase III trial"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01860976","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-8501","authenticated-orcid":false,"given":"Iain B","family":"McInnes","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6884-4301","authenticated-orcid":false,"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, IRCCS\u2014Fondazione Policlinico Universitario A. Gemelli\u2014Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-0060","authenticated-orcid":false,"given":"Maria-Antonietta","family":"D'Agostino","sequence":"additional","affiliation":[{"name":"Rheumatology, Universit\u00e9 Versailles Saint-Quentin en Yvelines, Ambroise Par\u00e9 Hospital, APHP, Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Le Bars","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Rueil-Malmaison, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris A","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[{"name":"Excelya, Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"2025090313562791000_5.1.e000934.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker349"},{"key":"2025090313562791000_5.1.e000934.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025090313562791000_5.1.e000934.3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/imt-2018-0014","article-title":"Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders","volume":"10","author":"Zizzo","year":"2018","journal-title":"Immunotherapy"},{"key":"2025090313562791000_5.1.e000934.4","unstructured":"Orencia prescribing information, 2017. Available: http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf [Accessed 2 Feb 2018]."},{"issue":"Suppl 2","key":"2025090313562791000_5.1.e000934.5","first-page":"231.2","article-title":"THU0106\u2005In patients with rheumatoid arthritis and an inadequate response to methotrexate, does body mass index influence the efficacy of abatacept on inflammation when measured by power doppler ultrasonography? Results from the appraise study","volume":"74","author":"D'Agostino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090313562791000_5.1.e000934.6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10067-016-3505-5","article-title":"Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the \"pan-European registry collaboration for abatacept (PANABA)","volume":"36","author":"Iannone","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025090313562791000_5.1.e000934.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2025090313562791000_5.1.e000934.8","first-page":"233","article-title":"Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the Aphrodite data","volume":"22","author":"Cassano","year":"2008","journal-title":"J Biol Regul Homeost Agents"},{"key":"2025090313562791000_5.1.e000934.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"2025090313562791000_5.1.e000934.10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/eci.12691","article-title":"Body mass index and response to abatacept in rheumatoid arthritis","volume":"46","author":"Gardette","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2025090313562791000_5.1.e000934.11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2016.10.011","article-title":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective action study","volume":"84","author":"Mariette","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2025090313562791000_5.1.e000934.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.03.007"},{"key":"2025090313562791000_5.1.e000934.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes242"},{"key":"2025090313562791000_5.1.e000934.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.30136"},{"key":"2025090313562791000_5.1.e000934.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21768"},{"key":"2025090313562791000_5.1.e000934.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"2025090313562791000_5.1.e000934.17","doi-asserted-by":"crossref","unstructured":"Ford AR , Siegel M , Bagel J , et al . Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National psoriasis Foundation: a systematic review. JAMA Dermatol 2018;154.doi:10.1001\/jamadermatol.2018.1412","DOI":"10.1001\/jamadermatol.2018.1412"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:56:37Z","timestamp":1756932997000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,5,30]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/rmdopen-2019-000934"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000934","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}